IDERA PHARMACEUTICALS, INC. IDRA Cash Flow

Idera pharmaceuticals, inc. (IDRA)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash Flows from Operating Activities:
Net income (loss)
-36,724	-56,515	-45,433	-45,905	-50,760	-59,881	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-32,814	-28,097	-23,380	-18,226	-15,934	-15,865	-16,161	-19,240	-20,602	-21,422	-23,817	-23,776	0	0	0
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Non-employee stock option expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	143	174	522	253	24	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation
3,579	3,845	4,088	4,452	5,101	5,674	6,009	6,305	10,525	10,720	10,885	10,892	6,915	6,847	6,556	6,070	5,812	5,442	6,249	5,871	5,133	4,322	2,490	2,200	1,680	1,398	1,462	1,491	1,761	2,096	2,259	2,409	2,653	2,725	0	0	0
Warrant liability revaluation income
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Future tranche right liability revaluation income
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from disposition of assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Issuance of common stock for services rendered
132	129	112	111	97	97	108	121	130	150	162	182	183	172	161	126	135	122	110	106	87	82	0	0	0	-	-	-	0	-	-	-	-1	1	0	0	0
Decrease in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Issuance of common stock for services rendered
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	38	0	0	0
Accretion of discounts on short-term investments
209	372	0	0	0	-	-	-	-	-94	-194	-298	-445	-566	-668	-760	-708	-599	-461	-316	-253	-213	0	0	0	-	-	-	-	-	-	-	-	-62	0	0	0
Unrealized gain on available-for-sale securities
-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization expense
109	120	131	178	298	432	582	699	739	746	731	707	675	656	626	592	544	488	417	341	276	206	166	140	126	137	0	0	0	-	-	-	-	-	-	-	-
Gain on disposal of property and equipment
-	10	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0
Changes in operating assets and liabilities:
Prepaid expenses and other assets
271	2,160	1,462	-2,225	-800	-2,717	-1,558	-286	-1,584	1,962	527	1,103	1,095	-1,064	774	1,502	1,403	1,889	1,264	766	575	329	705	634	984	676	253	-43	-81	-57	-327	-592	-817	-640	0	0	0
Accounts payable, accrued expenses, and other liabilities
1,737	-1,105	-2,578	-7,535	-5,976	-866	2,522	6,696	6,273	1,674	658	1,088	1,617	1,988	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable, accrued expenses, and other liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	4,291	3,235	1,293	74	-1,720	-2,032	-1,737	-2,415	-2,036	-1,530	-643	174	0	0	0
Deferred revenue
-	-	-	-	-	-566	0	0	0	-	-	-	-	-1,111	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-41,889	-44,498	-45,643	-46,594	-50,526	-51,916	-51,944	-52,036	-52,360	-55,259	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-19,377	-19,082	-18,712	-19,192	0	0	0
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-43,132	-	-43,841	-40,133	-36,428	-31,321	-26,272	-22,888	-21,040	-17,137	0	0	0	-	-	-	-	-	-	-	-
Cash Flows from Investing Activities:
Purchases of available-for-sale securities
14,552	44,502	0	0	0	-	-	-	-	-	-	-	-	2,946	2,946	9,856	62,378	63,106	84,110	77,200	26,681	23,623	0	0	0	-	-	-	-	-	-	-	-	1,025	0	0	0
Proceeds from maturity of available-for-sale securities
0	-	-	-	-	-	-	-	-	28,270	29,670	37,145	40,227	32,746	35,764	37,114	32,057	29,420	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	18,585	0	0	0
Proceeds from the sale of property and equipment
-	11	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of available-for-sale securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,974	1,974	1,974	999	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of property and equipment
14	11	15	44	65	75	177	148	190	206	139	241	348	408	437	618	712	727	861	936	1,186	1,093	896	541	20	9	0	0	0	-	-	-	-	23	0	0	0
Net cash used in investing activities
30,286	-2,402	-8,504	-11,879	-35,252	215	1,416	2,427	11,360	28,064	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17,639	0	0	0
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-29,059	-	-58,255	-61,420	-16,151	-20,601	-10,846	-10,491	-9,967	-9,340	0	0	0	-	-	-	-	-	-	-	-
Proceeds from common stock financings, net
5,119	5,298	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other
-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of common stock warrants and options and employee stock purchases
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Dividends paid
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,227	829	640	583	0	0	0	-	-	-	-
Proceeds from employee stock purchases
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0
Proceeds from employee stock purchases
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other
-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from employee stock purchases
-	-	-	-	-	-	0	0	277	-	0	0	0	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of common stock options and warrants
-	-	-	-	-	-	-	-	0	-	-	-	-	2,000	1,670	2,270	2,461	2,546	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prior year financing transaction costs paid in current year
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-
Proceeds from exercise of common stock warrants and options and employee stock purchases
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Dividends paid
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	798	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Payments on note payable
-	-	-	-	-	209	285	359	300	292	284	276	268	261	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments on capital leases
-	-	-	-	-	-	-	-	-	11	10	7	9	7	8	11	10	10	9	7	6	5	5	4	4	4	0	0	0	-	-	-	-	8	0	0	0
Net cash used in financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,797	-	81,601	83,036	84,104	45,615	46,860	71,964	85,606	42,659	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by financing activities
15,314	15,488	3,985	4,000	2,206	10,192	69,049	68,996	68,765	59,157	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,653	8,819	8,995	9,116	0	0	0
Net decrease in cash and cash equivalents
3,711	-31,412	-50,162	-54,473	-83,572	-41,509	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net decrease in cash, cash equivalents and restricted cash
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosure of cash flow information:
Increase to right-of-use asset upon adoption of ASC 842
-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase to lease liability upon adoption of ASC 842
-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosure of non-cash financing and investing activities:
Capitalized offering costs in accounts payable and accrued expenses
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5,842	-12,305	-70,394	6,615	-20,495	-18,517	31,525	-6,307	9,742	38,585	54,599	16,182	30,397	3,074	-12,540	-14,475	-9,726	-8,265	-2,420	7,563	0	0	0